Jardiance Cost in Oregon 2026: Prices, Insurance, Medicaid, and Compounded Options

What Is the Cash Price of Jardiance in Oregon in 2026?

The manufacturer's suggested retail price for Jardiance sits at approximately $680 per month for a 30-tablet supply of either the 10 mg or 25 mg strength at Oregon retail pharmacies in 2026. Without insurance or a discount program, most patients pay close to that list price. GoodRx and similar coupon platforms sometimes reduce the out-of-pocket cost to the $550, $640 range at major chains such as Fred Meyer, Rite Aid, and Walgreens locations across Portland, Eugene, and Bend. Prices fluctuate by zip code and by which pharmacy you use, so comparing at least three locations before filling is worth the few minutes it takes.

Empagliflozin belongs to the SGLT-2 inhibitor class. The FDA approved it for type 2 diabetes management in 2014, then expanded indications to cover heart failure with reduced ejection fraction in 2016 and heart failure with preserved ejection fraction and chronic kidney disease (CKD) in subsequent label updates [1]. Each of those indications affects which insurance tier the drug lands on and, in turn, what Oregonians actually pay at the counter.

The EMPA-REG OUTCOME trial (N=7,020) published in the New England England of Medicine in 2015 demonstrated that empagliflozin 10 mg or 25 mg added to standard care reduced the composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke by 14% relative to placebo (hazard ratio 0.86; 95% CI 0.74, 0.99; P<0.001 for non-inferiority, P=0.04 for superiority) [2]. That landmark result gave payers clinical justification to cover the drug, but coverage rules still vary widely by plan type.

Does Oregon Medicaid (OHP) Cover Jardiance?

Oregon Health Plan covers Jardiance with prior authorization. The drug sits in a non-preferred brand tier on the OHP preferred drug list, which means prescribers must document that a preferred SGLT-2 inhibitor or first-line agent was tried or is contraindicated before OHP will approve empagliflozin. For type 2 diabetes, OHP generally expects evidence of metformin use (or documented intolerance) before approving an SGLT-2 inhibitor [3].

For heart failure and CKD indications, the prior authorization criteria are somewhat different. OHP's Pharmacy and Therapeutics committee has acknowledged the cardiovascular and renal outcomes data. The EMPEROR-Reduced trial (N=3,730) showed empagliflozin reduced the composite of cardiovascular death or hospitalization for heart failure by 25% relative to placebo (HR 0.75; 95% CI 0.65, 0.86; P<0.001) [4]. Citing that trial in a PA request for a heart failure patient substantially strengthens the clinical justification.

Once approved, OHP enrollees typically pay $0 to $4 per fill depending on their OHP benefit package. The approval window is usually 12 months before re-authorization is required. If your prescriber submits documentation showing ongoing benefit (hemoglobin A1c reduction, stable eGFR, reduced hospitalizations), renewal approval is routine rather than exceptional.

The Oregon Health Authority publishes updated preferred drug list information quarterly at oregon.gov; confirm the current tier status before submitting a PA, because tier placement can shift when new generics or biosimilars enter a class [3].

Which Commercial Insurance Plans Cover Jardiance in Oregon?

Most major commercial plans sold through Cover Oregon or employer groups cover empagliflozin, though tier placement varies. Kaiser Permanente Northwest, Regence BlueCross BlueShield of Oregon, Providence Health Plan, and Moda Health each maintain their own formularies. Tier 3 (preferred brand) placement is common; some plans place it at Tier 4 (non-preferred brand), which substantially raises cost-sharing.

A 2022 analysis published in JAMA Internal Medicine found that SGLT-2 inhibitor coverage varied significantly across Medicare Part D plans, with 22% of plans requiring prior authorization for empagliflozin in that year [5]. Commercial plan rules in Oregon follow similar patterns. Checking your plan's formulary at its member portal or calling the pharmacy benefits line before the first fill avoids surprise charges.

For Medicare Part D specifically, the Inflation Reduction Act caps out-of-pocket drug costs at $2,000 per year starting in 2025, which meaningfully reduces annual exposure for patients who previously reached the coverage gap [6]. Oregon residents on Medicare who use Jardiance year-round are among those most likely to benefit from that cap.

How Does the Boehringer Ingelheim and Lilly Savings Card Work in Oregon?

Commercially insured patients in Oregon who are not enrolled in any federal or state government health program (including OHP, Medicare, or Medicaid) may use the Boehringer Ingelheim and Lilly Jardiance savings card. Eligible patients may pay as little as $0 per month, with a maximum savings cap that the manufacturers set annually [7].

The enrollment process is straightforward. Patients register at jardiance.com or through a participating pharmacy, then present the savings card (physical or digital) at checkout. The manufacturer's copay adjustment applies after the insurance plan's negotiated rate, so the card covers the remaining patient cost-share up to the program's monthly limit. There is no income requirement for the commercial copay card, but government-program enrollees are explicitly excluded by federal anti-kickback statute.

Oregon residents who are uninsured do not qualify for the standard savings card but may apply for the Boehringer Ingelheim Cares Foundation patient assistance program, which can provide Jardiance at no cost to qualifying low-income patients [7]. Income thresholds change annually; confirming current eligibility criteria directly with the manufacturer is the most reliable approach.

Is Compounded Empagliflozin Legal in Oregon?

Yes. Compounded empagliflozin prepared by a state-licensed 503A compounding pharmacy is legal in Oregon, provided the compounding pharmacy meets Oregon State Board of Pharmacy requirements and the prescription is issued by a licensed prescriber for an individual patient [8]. Compounded preparations are not FDA-approved finished drug products, so patients and prescribers should understand that the safety, purity, and potency data backing the brand-name product do not automatically extend to compounded versions.

The FDA classifies empagliflozin as a small-molecule drug not currently on any shortage list and has not added it to any list of drugs that may be bulk-compounded under 503B outsourcing facility rules. That means compounded empagliflozin is available only through 503A pharmacies on a patient-specific prescription basis, not through large-volume 503B outsourcing facilities supplying clinics in bulk [8].

Cash prices at Oregon 503A compounding pharmacies vary. Some telehealth platforms pair with compounding pharmacies to offer empagliflozin preparations at substantially reduced prices compared to the brand-name list price. Patients should ask the compounding pharmacy to provide a certificate of analysis from a third-party laboratory confirming potency and purity before starting any compounded medication.

The HealthRX clinical team recommends the following decision framework for Oregon patients evaluating brand vs. compounded empagliflozin:

1. Check OHP or commercial plan coverage first. A $0 or low copay on brand Jardiance makes compounding unnecessary.
2. If insured cost-share exceeds $100/month, apply the Boehringer Ingelheim savings card before exploring compounding.
3. If uninsured or savings card does not apply, contact the Boehringer Ingelheim Cares Foundation for patient assistance.
4. If none of the above reduces cost adequately, ask your prescriber whether a licensed Oregon 503A pharmacy can provide compounded empagliflozin with a verified certificate of analysis.

Can I Get a Jardiance Prescription via Telehealth in Oregon?

Oregon law permits telehealth prescribing of Jardiance for established clinical indications. A prescriber licensed in Oregon may evaluate a patient via video or, in some circumstances, synchronous audio-only visit and issue a prescription for empagliflozin without an in-person visit, provided the standard of care for diagnosis and monitoring is met [9]. That typically includes a documented diagnosis (type 2 diabetes, heart failure, or CKD), a recent HbA1c or eGFR result, and a medication history review.

The Ryan Haight Online Pharmacy Consumer Protection Act does not restrict prescribing of non-controlled substances like empagliflozin, so the telehealth prescribing rules for Jardiance are governed by Oregon Medical Board telemedicine guidelines rather than DEA controlled-substance telehealth rules [9]. Oregon's rules require that the prescriber establishes a valid patient-provider relationship before prescribing, which a properly conducted telehealth visit satisfies.

HealthRX clinicians licensed in Oregon can evaluate and prescribe empagliflozin via telehealth for eligible patients with type 2 diabetes, heart failure, or CKD, following the same clinical standards applied in a traditional office setting.

What Are the Clinical Outcomes That Justify the Cost?

The cost conversation gains context when placed alongside the outcomes evidence. The EMPA-REG OUTCOME trial (N=7,020) showed a 38% relative risk reduction in cardiovascular death compared with placebo (HR 0.62; 95% CI 0.49, 0.77; P<0.001) [2]. That is not a surrogate endpoint but a reduction in actual deaths. For patients with established cardiovascular disease, the cost-effectiveness calculus shifts substantially.

The EMPEROR-Preserved trial (N=5,988) extended the heart failure benefit to patients with ejection fraction above 40%, showing a 21% relative risk reduction in cardiovascular death or heart failure hospitalization (HR 0.79; 95% CI 0.69, 0.90; P<0.001) [10]. The American College of Cardiology and American Heart Association 2022 heart failure guidelines gave empagliflozin a Class IIa recommendation for heart failure with preserved ejection fraction based substantially on that trial [11].

For CKD, the EMPA-KIDNEY trial (N=6,609) showed a 28% relative risk reduction in the composite of kidney disease progression or cardiovascular death (HR 0.72; 95% CI 0.64, 0.82; P<0.001) [12]. That evidence base supports a strong case for insurance coverage and prior authorization approval when a prescriber documents the CKD indication clearly.

The ADA Standards of Medical Care in Diabetes 2024 give empagliflozin a Grade A recommendation for patients with type 2 diabetes and established cardiovascular disease, heart failure, or CKD, stating: "For patients with type 2 diabetes and established cardiovascular disease, SGLT-2 inhibitors with demonstrated cardiovascular benefit are recommended as part of the glucose-lowering regimen" [13].

What Are the Jardiance Dosing Options That Affect Cost?

Jardiance comes in two strengths: 10 mg and 25 mg. Both are dosed once daily, and both carry the same list price at Oregon pharmacies. The FDA label supports starting at 10 mg once daily for type 2 diabetes, with an option to increase to 25 mg if additional glycemic control is needed and tolerability is confirmed [1]. For heart failure and CKD indications, 10 mg once daily is the standard dose used in the outcomes trials.

Because both strengths cost the same at retail, dose escalation from 10 mg to 25 mg does not increase pharmacy cost. Formulary copay tiers are applied per fill regardless of strength. That makes the 10 mg starting dose essentially a free trial of tolerability before any decision to increase.

Common side effects include genital mycotic infections (affecting roughly 10% of women and 4% of men in clinical trials), urinary tract infections, and volume depletion [1]. Patients with eGFR below 20 mL/min/1.73 m² should not use empagliflozin for glycemic control, though the CKD outcomes indication extends use to lower eGFR ranges under specific protocols [12].

Oregon-Specific Resources for Reducing Jardiance Cost

Several Oregon-specific resources reduce out-of-pocket cost beyond the manufacturer savings card.

The Oregon Prescription Drug Program (OPDP) negotiates rates with participating pharmacies and is available to all Oregon residents regardless of insurance status. OPDP discounts on brand-name drugs are modest but can shave $20, $40 per fill on Jardiance at participating pharmacies. Enrollment is free at Oregon.gov/OHA [3].

Oregon's Extra Help program (also called the Low Income Subsidy) assists Medicare beneficiaries with limited income and resources in paying Part D premiums, deductibles, and cost-sharing. An Oregon Medicare enrollee on Extra Help who uses Jardiance may pay as little as a few dollars per fill depending on income tier [6].

NeedyMeds.org maintains a database of patient assistance programs and discount cards that is updated frequently and covers Oregon pharmacies. The Boehringer Ingelheim Cares Foundation listing on that platform allows patients to apply directly and track application status. Community health centers (FQHCs) in Oregon, including outside Portland in rural counties, can often assist with manufacturer assistance applications and may stock samples for bridging coverage gaps.

How Jardiance Compares to Other SGLT-2 Inhibitors Available in Oregon

Dapagliflozin (Farxiga) and canagliflozin (Invokana) are the other commercially available SGLT-2 inhibitors with outcomes data. Dapagliflozin carries similar cardiovascular and renal outcomes evidence from the DAPA-HF trial (N=4,744; HR 0.74 for CV death or worsening HF; P<0.001) [14] and the DAPA-CKD trial [15]. List prices for Farxiga and Invokana are broadly comparable to Jardiance, so formulary tier placement at your specific plan is the deciding factor for Oregon patients, not the list price difference.

Generic dapagliflozin is not yet available in the United States as of early 2025; neither is generic empagliflozin. Patent expirations that might bring generics to Oregon pharmacies are expected in the mid-2020s, but launch timing is subject to litigation and FDA review. Patients hoping for a generic should confirm the current status with their pharmacist rather than relying on projected dates.